Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Opportunistic Infection
Lamivudine Has Protective Effect Against Hepatitis B in HIV Patients
November 12th, 2000
Individuals who are infected with the human immunodeficiency virus (HIV) are highly susceptible to a number of other illnesses, including tuberculosis, hepatitis, and certain types of cancer. Researchers at the U.S. Centers for Disease Control and Prevention recently presented evidence that HIV infected individuals who are at risk for acquiring hepatitis B virus (HBV) might be protected against that disease by adding lamivudine therapy to their antiretroviral drug regimens. This suggestion was made as the result of a review of patient information in records from HIV surveillance programs in 10 cities in the United States. ...
Source: Medical Letter on the CDC & FDA (2000-11-12)
|
